Kenneth F Mace
Overview
Explore the profile of Kenneth F Mace including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linnebjerg H, Choi S, Lam E, Mace K, Hodgson T, Sinha V
Clin Pharmacol Drug Dev
. 2016 May;
5(3):216-24.
PMID: 27163501
The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long-acting basal insulin analogue, was evaluated in 5 groups of subjects with varying degrees of renal function based on creatinine clearance:...
2.
Sinha V, Choi S, Soon D, Mace K, Yeo K, Lim S, et al.
J Clin Pharmacol
. 2014 Feb;
54(7):792-9.
PMID: 24504686
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541 pharmacokinetics (PK), glucodynamics (GD), and tolerability in healthy subjects. In Study...
3.
Parkes D, Mace K, Trautmann M
Expert Opin Drug Discov
. 2012 Dec;
8(2):219-44.
PMID: 23231438
Introduction: The GLP-1 receptor agonist exenatide is synthetic exendin-4, a peptide originally isolated from the salivary secretions of the Gila monster. Exenatide was developed as a first-in-class diabetes therapy, with...
4.
de la Pena A, Riddle M, Morrow L, Jiang H, Linnebjerg H, Scott A, et al.
Diabetes Care
. 2011 Oct;
34(12):2496-501.
PMID: 21994429
Objective: Human regular U-500 (U-500R) insulin (500 units/mL) is increasingly being used clinically, yet its pharmacokinetics (PK) and pharmacodynamics (PD) have not been well studied. Therefore, we compared PK and...
5.
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing
Fineman M, Flanagan S, Taylor K, Aisporna M, Shen L, Mace K, et al.
Clin Pharmacokinet
. 2010 Dec;
50(1):65-74.
PMID: 21142268
Background And Objectives: Exenatide is a glucagon-like peptide-1 receptor agonist, available in an immediate-release (IR), twice-daily formulation, which improves glycaemic control through enhancement of glucose-dependent insulin secretion, suppression of inappropriately...
6.
Soon D, Kothare P, Linnebjerg H, Park S, Yuen E, Mace K, et al.
J Clin Pharmacol
. 2006 Sep;
46(10):1179-87.
PMID: 16988207
Exenatide, a treatment for type 2 diabetes, slows gastric emptying as part of its pharmacologic action and may alter the absorption of concomitant oral drugs. This open-label, 2-period, fixed-sequence study...
7.
Kothare P, Soon D, Linnebjerg H, Park S, Chan C, Yeo A, et al.
J Clin Pharmacol
. 2005 Aug;
45(9):1032-7.
PMID: 16100297
This open-label study investigated the effect of exenatide coadministration on the steady-state plasma pharmacokinetics of digoxin. A total of 21 healthy male subjects received digoxin (day 1, 0.5 mg twice...